Depolymerized holothurian glycosaminoglycan and heparin inhibit the intrinsic tenase complex by a common antithrombin-independent mechanism

Blood

Volumn 107, Issue 10, 2006, Pages 3876-3882

  Sheehan, John P ^a   Walke, Erik N ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9A; CHONDROITIN SULFATE; DEPOLYMERIZED HOLOTHURIAN GLYCOSAMINOGLYCAN; GLYCOSAMINOGLYCAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID; THROMBIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BLOOD CLOTTING; CELL STRAIN HEK293; CONTROLLED STUDY; DEPOLYMERIZATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MODEL; PRIORITY JOURNAL;

EID: 33646543029     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-07-3043     Document Type: Article

References (51)

1. Murray GD. Heparin in thrombosis and embolism. Br J Surg. 1940;27:567-598.
2. Olson ST, Bjork I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions: resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem. 1992;267:12528-12538.
3. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med. 1997;337:657-662.
4. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med. 1996;334:682-687.
5. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681.
6. Olson ST, Bjork I. Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction: elucidation from salt concentration effects. J Biol Chem. 1991;266:6353-6364.
7. Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost. 1990;16(suppl):12-18.
8. Wiebe EM, Stafford AR, Fredenburgh JC, Weitz JI. Mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide. J Biol Chem. 2003;278:35767-35774.
9. Bedsted T, Swanson R, Chuang YJ, Bock PE, Bjork I, Olson ST. Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites. Biochemistry. 2003;42:8143-8152.
10. Gray E, Cesmeli S, Lormeau JC, Davies AB, Lane DA. Low affinity heparin is an antithrombotic agent. Thromb Haemost. 1994;71:203-207.
11. Barrow RT, Healey JF, Lollar P. Inhibition by heparin of thrombin-catalyzed activation of the factor VIII-von Willebrand factor complex. J Biol Chem. 1994;269:593-598.
12. Barrow RT, Parker ET, Krishnaswamy S, Lollar P. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator. J Biol Chem. 1994;269:26796-26800.
13. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood. 1996;88:3432-3445.
14. Esmon CT, Lollar P. Involvement of thrombin anion-binding exosites 1 and 2 in the activation of factor V and factor VIII. J Biol Chem. 1996;271:13882-13887.
15. Lian F, He L, Colwell NS, Lollar P, Tollefsen DM. Anticoagulant activities of a monoclonal antibody that binds to exosite II of thrombin. Biochemistry. 2001;40:8508-8513.
16. Sheehan JP, Kobbervig CE, Kirkpatrick HM. Heparin inhibits the intrinsic tenase complex by interacting with an exosite on factor IXa. Biochemistry. 2003;42:11316-11325.
17. Yuan QP, Walke EN, Sheehan JP. The factor IXa heparin-binding exosite is a cofactor interactive site: mechanism for antithrombin-independent inhibition of intrinsic tenase by heparin. Biochemistry. 2005;44:3615-3625.
18. Nagase H, Kitazato KT, Sasaki E, Hattori M, Kitazato K, Saito H. Antithrombin III-independent effect of depolymerized holothurian glycosaminoglycan (DHG) on acute thromboembolism in mice. Thromb Haemost. 1997;77:399-402.
19. Kitazato K, Kitazato KT, Nagase H, Minamiguchi K. DHG, a new depolymerized holothurian glycosaminoglycan, exerts an antithrombotic effect with less bleeding than unfractionated or low molecular weight heparin, in rats. Thromb Res. 1996;84:111-120.
20. Minamiguchi K, Kitazato KT, Sasaki E, Nagase H, Kitazato K. The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs. Thromb Haemost. 1997;77:1148-1153.
21. Minamiguchi K, Kitazato KT, Nagase H, Sasaki E, Ohwada K, Kitazato K. Depolymerized holothurian glycosaminoglycan (DHG), a novel alternative anticoagulant for hemodialysis, is safe and effective in a dog renal failure model. Kidney Int. 2003;63:1548-1555.
22. Nagase H, Enjyoji K, Minamiguchi K, et al. Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin. Blood. 1995;85:1527-1534.
23. Nagase H, Enjyoji K, Shima M, et al. Effect of depolymerized holothurian glycosaminoglycan (DHG) on the activation of factor VIII and factor V by thrombin. J Biochem (Tokyo). 1996;119:63-69.
24. MacDonald RC, MacDonald RI, Menco BP, Takeshita K, Subbarao NK, Hu LR. Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim Biophys Acta. 1991;1061:297-303.
25. Chen P, Toribara T, Warner H. Microdetermination of phosphorus. Anal Chem. 1956;28:1756-1758.
26. Chang J, Jin J, Lollar P, et al. Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J Biol Chem. 1998;273:12089-12094.
27. Lozier JN, Monroe DM, Stanfield-Oakley S, et al. Factor IX New London: substitution of proline for glutamine at position 50 causes severe hemophilia B. Blood. 1990;75:1097-1104.
28. Myszka DG. Kinetic, equilibrium, and thermodynamic analysis of macromolecular interactions with BIACORE. Methods Enzymol. 2000;323:325-340.
29. Limbird L. Cell Surface Receptors: A Short Course on Theory and Methods. 2nd ed. Boston, MA: Kluwer Academic Publishers; 1995.
30. Segel IH. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. New York, NY: John Wiley and Sons; 1975.
31. Dixon M, Webb E. Enzymes. 3rd ed. New York. NY: Academic Press; 1979.
32. Sheehan JP, Phan TM. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism. Biochemistry. 2001;40:4980-4989.
33. Krishnaswamy S, Betz A. Exosites determine macromolecular substrate recognition by prothrombinase. Biochemistry. 1997;36:12080-12086.
34. Wilkens M, Krishnaswamy S. The contribution of factor Xa to exosite-dependent substrate recognition by prothrombinase. J Biol Chem. 2002;277:9366-9374.
35. Lollar P, Parker CG. pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem. 1990;265:1688-1692.
36. Fay PJ, Beattie TL, Regans LMO, Brien LM, Kaufman RJ. Model for the factor VIIIa-dependent decay of the intrinsic factor Xase: role of subunit dissociation and factor IXa-catalyzed proteolysis. J Biol Chem. 1996;271:6027-6032.
37. Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin, I: an empirical study. J Biol Chem. 1994;269:23357-23366.
38. van 't Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem. 1997;272:4367-4377.
39. van 't Veer C, Golden NJ, Kalafatis M, Mann KG. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation: synergistic effect in combination with tissue factor pathway inhibitor. J Biol Chem. 1997;272:7983-7994.
40. Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem. 2002;277:18322-18333.
41. Krishnaswamy S. Exosite-driven substrate specificity and function in coagulation. J Thromb Haemost. 2005;3:54-67.
42. Lenting PJ, Donath MJ, van Mourik JA, Mertens K. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem. 1994;269:7150-7155.
43. Lenting PJ, van de Loo JW, Donath MJ, van Mourik JA, Mertens K. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem. 1996;271:1935-1940.
44. Jenkins PV, Freas J, Schmidt KM, Zhou Q, Fay PJ. Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex. Blood. 2002;100:501-508.
45. Jenkins PV, Dill JL, Zhou Q, Fay PJ. Clustered basic residues within segment 484-510 of the factor VIIIa A2 subunit contribute to the catalytic efficiency for factor Xa generation. J Thromb Haemost. 2004;2:452-458.
46. Benedict CR, Ryan J, Wolitzky B, et al. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest. 1991;88:1760-1765.
47. Choudhri TF, Hoh BL, Prestigiacomo CJ, et al. Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage. J Exp Med. 1999;190:91-99.
48. Spanier TB, Chen JM, Oz MC, et al. Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1998;116:860-869.
49. Feuerstein GZ, Patel A, Toomey JR, et al. Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. Arterioscler Thromb Vasc Biol. 1999;19:2554-2562.
50. Refino CJ, Jeet S, DeGuzman L, Bunting S, Kirchhofer D. A human antibody that inhibits factor IX/IXa function potently inhibits arterial thrombosis without increasing bleeding. Arterioscler Thromb Vasc Biol. 2002;22:517-522.
51. Fay PJ, Koshibu K. The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem. 1998;273:19049-19054.